Guidance: MenB vaccine: patient group direction template

This patient group direction (PGD) template supports the administration of MenB vaccine to individuals from 8 weeks of age eligible for the national routine meningococcal group B vaccination programme and to individuals for the prevention of secondary cases of meningococcal group B disease in accordance with the guidance for the public health management of meningococcal disease in the UK.

The PGD template has been updated to include use of Trumenba® (f rLP2086) vaccine for the prevention of secondary cases of meningococcal group B disease as per guidance for the public health management of meningococcal disease in the UK as an alternative to Bexsero® vaccine where the infecting strain is confirmed or predicted not to be covered by Bexsero® vaccine.

Note: Trumenba® (f rLP2086) vaccine is not used for the national routine childhood immunisation programme.

MenB vaccine PGD template version 9.0 is valid from 1 December 2026 to 1 December 2029.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.